#ModernaRisesOver12% #ModernaRisesOver12%
Moderna shares surged more than 12%, making it one of the best-performing stocks in the S&P 500, after the company unveiled promising new pipeline developments during its Science Day investor event.
Key points:
Investors reacted positively to Moderna's first in vivo CAR-T program targeting autoimmune diseases, including systemic lupus erythematosus.
The company highlighted progress across its cancer, autoimmune, and next-generation mRNA programs, reinforcing confidence that it is expanding beyond COVID-19 vaccines.
Analysts also pointed to upcoming catalysts, including an FDA decision on Moderna's seasonal flu vaccine later this year, as additional drivers for investor optimism.
Moderna shares surged more than 12%, making it one of the best-performing stocks in the S&P 500, after the company unveiled promising new pipeline developments during its Science Day investor event.
Key points:
Investors reacted positively to Moderna's first in vivo CAR-T program targeting autoimmune diseases, including systemic lupus erythematosus.
The company highlighted progress across its cancer, autoimmune, and next-generation mRNA programs, reinforcing confidence that it is expanding beyond COVID-19 vaccines.
Analysts also pointed to upcoming catalysts, including an FDA decision on Moderna's seasonal flu vaccine later this year, as additional drivers for investor optimism.